Business Context and Reporting Period
This Form 8-K is filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on November 19, 2024. The report addresses a notice of delisting or failure to satisfy continued listing standards received from The Nasdaq Stock Market.
Key Financial Metrics
- Stockholders' Equity: $707,000 (as reported in the Form 10-Q for the period ended September 30, 2024).
- Minimum Equity Requirement: $2.5 million (Nasdaq Listing Rule 5550(b)(1)).
- Minimum Bid Price: The company has a separate deficiency regarding the failure to maintain a closing bid price of $1.00 per share.
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels beyond the equity figure.
Material Changes and Listing Status
The company received a notice from Nasdaq stating it is not in compliance with the minimum stockholders' equity requirement. Additionally, the company remains under a separate deficiency notice regarding the minimum bid price requirement, which was transferred to the Nasdaq Capital Market on August 1, 2024. The listing remains fully effective for now, but the company faces potential delisting if compliance is not regained.
Guidance, Outlook, and Risks
- Compliance Deadlines:
- Equity Requirement: The company has 45 calendar days (until January 3, 2025) to submit a plan to regain compliance. If accepted, an extension of up to 180 days may be granted.
- Bid Price Requirement: The company has until January 27, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.
- Management Actions: The company is evaluating courses of action, including a potential reverse stock split, to address the bid price deficiency. It intends to submit a plan for the equity deficiency.
- Risks: There is no assurance that a compliance plan will be accepted or that the company will regain compliance. Failure to comply could result in delisting. Appeals to a Nasdaq Hearings Panel are possible but not guaranteed to be successful.
Investor Verification Checklist
- Verify the company's current stockholders' equity and any recent capital raise activities intended to meet the $2.5 million threshold.
- Monitor the daily closing bid price of CARA stock to determine if it meets the $1.00 requirement for ten consecutive days before January 27, 2025.
- Review the company's upcoming filings for the formal compliance plan submission to Nasdaq by January 3, 2025.
- Assess the likelihood and terms of a potential reverse stock split if the bid price deficiency persists.